Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters

Kaohsiung Journal of Medical Sciences

Volumn 22, Issue 4, 2006, Pages 177-183

  Lin, Tsung Hsien ^a   Voon, Wen Chol ^a   Yen, Hsueh Wei ^a   Huang, Chih Hsin ^a   Su, Ho Ming ^a   Lai, Wen Ter ^a   Sheu, Sheng Hsiung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Fibrinolysis; Hypertension; Lercanidipine; Losartan; Plasminogen activator inhibitor

Indexed keywords

ANTIHYPERTENSIVE AGENT; D DIMER; FIBRINOGEN; LERCANIDIPINE; LOSARTAN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DERMATITIS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FEMALE; FIBRINOLYSIS; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RIGIDITY; SLEEP DISORDER; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; VERTIGO;

EID: 33646249363     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70304-3     Document Type: Article

References (19)

1. Glueck CJ, Glueck HI, Hamer T, et al. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci 1994;307:317-24.
2. Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005;45:907-13.
3. Hoffmeister HM, Heller W, Seipel L. Activation markers of coagulation and fibrinolysis: alterations and predictive value in acute coronary syndromes. Thromb Haemost 1999;82 (Suppl 1):76-9.
4. Seljeflot I, Moan A, Kjeldsen S, et al. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996;27:1299-1304.
5. Koh KK, Chung WJ, Ahn JY, et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2004;177:155-60.
6. Pahor M, Franse LV, Deitcher SR, et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002;105:457-61.
7. Gleerup G, Mehlsen J, Winther K. Does calcium channel blockade and beta-adrenergic blockade affect platelet function and fibrinolysis to a varying degree? J Cardiovasc Pharmacol 1995;25:87-9.
8. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003; 63:2449-72.
9. Rachmani R, Levi Z, Zadok BS, et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther 2002;72:302-7.
10. Black HR. Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials. Clin Cornerstone 2004;6:53-66.
11. Pahor M, Psaty BM, Alderman MH, et al. The health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. Lancet 2000;356:1949-54.
12. Corsini A, Accomazzo MR, Canavesi M, et al. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press Suppl 1998;2:18-22.
13. Soma MR, Natali M, Donetti E, et al. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998;125:1471-6.
14. Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003;41:950-5.
15. Chen HC, Bouchie JL, Perez AS, et al. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol 2000;20:2297-302.
16. Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997;77:1189-95.
17. Zaman AK, Fujii S, Sawa H, et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation 2001;103:3123-8.
18. Materson BJ, Reda DJ, Cushman WC, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Am J Hypertens 1995;8:189-92.
19. Li Y, Liu G, Jiang B, et al. A comparison of initial treatment with losartan/HCTZ versus losartan monotherapy in Chinese patients with mild to moderate essential hypertension. Int J Clin Pract 2003;57:673-7.